Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 6, 2026, 2:56 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–23 of 23 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Mepolizumab SC Clear all
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Mepolizumab Adjunctive Therapy in Subjects With Severe Uncontrolled Refractory Asthma

NCT01691521
View directory record Official record
Conditions
Asthma
Interventions
Mepolizumab IV, Mepolizumab SC, IV Placebo, SC Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
580 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
21
States / cities
Birmingham, Alabama • Newport Beach, California • Riverside, California + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2018 · Synced Sep 6, 2026, 2:56 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate Efficacy and Safety of Mepolizumab for Frequently Exacerbating Chronic Obstructive Pulmonary Disease (COPD) Patients

NCT02105948
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Mepolizumab, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
837 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
20
States / cities
Newport Beach, California • Rochester, Minnesota • Saint Charles, Missouri + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2018 · Synced Sep 6, 2026, 2:56 PM EDT
Completed Phase 2 Interventional Results available

Dose Ranging Pharmacokinetics and Pharmacodynamics Study With Mepolizumab in Asthma Patients With Elevated Eosinophils

NCT01366521
View directory record Official record
Conditions
Asthma
Interventions
Mepolizumab
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
2
States / cities
Winston-Salem, North Carolina • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 10, 2017 · Synced Sep 6, 2026, 2:56 PM EDT
Completed Phase 3 Interventional Results available

A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype

NCT04718389
View directory record Official record
Conditions
Asthma
Interventions
GSK3511294 (Depemokimab), Mepolizumab, Benralizumab, Placebo, Standard of care (SoC), Pre-filled Syringes (PFS)
Biological · Drug · Device
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
1,717 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
119
States / cities
Birmingham, Alabama • Scottsboro, Alabama • Litchfield Park, Arizona + 94 more
Source: ClinicalTrials.gov public record
Updated May 17, 2026 · Synced Sep 6, 2026, 2:56 PM EDT
Completed Phase 3 Interventional Results available

MEA112997 Open-label Long Term Extension Safety Study of Mepolizumab in Asthmatic Subjects

NCT01691859
View directory record Official record
Conditions
Asthma
Interventions
Mepolizumab
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
347 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
11
States / cities
Long Beach, California • Riverside, California • Denver, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2023 · Synced Sep 6, 2026, 2:56 PM EDT
Completed Phase 3 Interventional Results available

Long-term Access Program (LAP) of Mepolizumab for Subjects Who Participated in Study MEA115921

NCT03298061
View directory record Official record
Conditions
Churg-Strauss Syndrome, Eosinophilic Granulomatosis With Polyangiitis
Interventions
Mepolizumab, Prednisolone
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
14
States / cities
Denver, Colorado • Bethesda, Maryland • Boston, Massachusetts + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2024 · Synced Sep 6, 2026, 2:56 PM EDT
Completed Phase 3 Interventional Results available

Study of Mepolizumab Autoinjector in Asthmatics

NCT03099096
View directory record Official record
Conditions
Asthma
Interventions
Mepolizumab
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
16
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2023 · Synced Sep 6, 2026, 2:56 PM EDT
Completed Phase 3 Interventional Results available

Study in Pediatrics With HypEREosinophilic Syndrome (SPHERE)

NCT04965636
View directory record Official record
Conditions
Hypereosinophilic Syndrome
Interventions
Mepolizumab
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
6 Years to 17 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
4
States / cities
Rochester, Minnesota • Cincinnati, Ohio • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Sep 6, 2026, 2:56 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Pharmacodynamic Biomarkers to Support Biosimilar Development: Interleukin-5 Antagonists

NCT04183192
View directory record Official record
Conditions
Healthy Subjects, Pharmacokinetics, Pharmacodynamics
Interventions
Mepolizumab, Reslizumab, Placebo
Biological
Lead sponsor
Food and Drug Administration (FDA)
Federal
Eligibility
18 Years to 55 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 21, 2024 · Synced Sep 6, 2026, 2:56 PM EDT
Completed Phase 3 Interventional Results available

Study of Mepolizumab Safety Syringe in Asthmatics

NCT03021304
View directory record Official record
Conditions
Asthma
Interventions
Mepolizumab
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
4
States / cities
Birmingham, Alabama • Los Angeles, California • Cincinnati, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2019 · Synced Sep 6, 2026, 2:56 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Mepolizumab in Subjects With Severe Hypereosinophilic Syndrome (HES)

NCT02836496
View directory record Official record
Conditions
Hypereosinophilic Syndrome
Interventions
Mepolizumab 300 mg, Placebo matching mepolizumab, Active OCS capsules (5 mg prednisolone or prednisone), Placebo matching OCS capsules
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
7
States / cities
San Diego, California • New Haven, Connecticut • Rochester, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2020 · Synced Sep 6, 2026, 2:56 PM EDT
Completed Phase 3 Interventional Results available

Mepolizumab as Add-on Treatment IN Participants With COPD Characterized by Frequent Exacerbations and Eosinophil Level

NCT04133909
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Mepolizumab, Placebo
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
806 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
88
States / cities
Birmingham, Alabama • Dothan, Alabama • Huntsville, Alabama + 72 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Sep 6, 2026, 2:56 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Compare the Pharmacokinetics of Mepolizumab as a Liquid Drug in a Safety Syringe or an Autoinjector Versus Lyophilised Drug

NCT03014674
View directory record Official record
Conditions
Asthma
Interventions
Lyophilized mepolizumab, Liquid mepolizumab, Prefilled autoinjector, Prefilled Safety Syringe
Biological · Device
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
246 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 2, 2019 · Synced Sep 6, 2026, 2:56 PM EDT
Completed Phase 3 Interventional Results available

A Multi-center, Open-label Extension, Safety Study of Mepolizumab in Subjects With Hypereosinophilic Syndrome (HES) From Study 200622

NCT03306043
View directory record Official record
Conditions
Hypereosinophilic Syndrome
Interventions
Mepolizumab
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
6
States / cities
La Jolla, California • New Haven, Connecticut • Rochester, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2020 · Synced Sep 6, 2026, 2:56 PM EDT
Completed Phase 3 Interventional Results available

A Study to Determine Long-term Safety of Mepolizumab in Asthmatic Subjects

NCT01842607
View directory record Official record
Conditions
Asthma
Interventions
Mepolizumab
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
651 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
20
States / cities
Long Beach, California • Newport Beach, California • Riverside, California + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2018 · Synced Sep 6, 2026, 2:56 PM EDT
Completed Phase 3 Interventional Results available

A Phase 3a, Repeat Dose, Open-label, Long-term Safety Study of Mepolizumab in Asthmatic Subjects

NCT02135692
View directory record Official record
Conditions
Asthma
Interventions
Mepolizumab, SOC
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
339 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
16
States / cities
Newport Beach, California • Riverside, California • Rolling Hills Estates, California + 13 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2019 · Synced Sep 6, 2026, 2:56 PM EDT
Completed Phase 4 Interventional Results available

Omalizumab to Mepolizumab Switch Study in Severe Eosinophilic Asthma Patients

NCT02654145
View directory record Official record
Conditions
Asthma
Interventions
Mepolizumab 100mg SC, Albuterol/salbutamol MDIs, Omalizumab
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
13
States / cities
Birmingham, Alabama • Riverside, California • Roseville, California + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2019 · Synced Sep 6, 2026, 2:56 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Efficacy and Safety of Benralizumab in EGPA Compared to Mepolizumab.

NCT04157348
View directory record Official record
Conditions
Eosinophilic Granulomatous Vasculitis
Interventions
Benralizumab, Mepolizumab, Placebo to Mepolizumab, Placebo to Benralizumab
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
9
States / cities
Denver, Colorado • Ann Arbor, Michigan • Rochester, Minnesota + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Sep 6, 2026, 2:56 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Mepolizumab as an Add-on Treatment in Chronic Obstructive Pulmonary Disease (COPD)

NCT02105961
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Mepolizumab, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
674 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
35
States / cities
Birmingham, Alabama • Mobile, Alabama • Riverside, California + 31 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2018 · Synced Sep 6, 2026, 2:56 PM EDT
Recruiting Phase 2 Interventional

Dupilumab as Add-On Therapy for Hypereosinophilic Syndrome With Partial Clinical Response to Eosinophil-Depleting Biologic Agents

NCT06477653
View directory record Official record
Conditions
Hypereosinophilic Syndrome
Interventions
dupilumab
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 99 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Sep 6, 2026, 2:56 PM EDT
Completed Phase 3 Interventional Results available

A Study to Investigate Mepolizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis

NCT02020889
View directory record Official record
Conditions
Churg-Strauss Syndrome
Interventions
Mepolizumab, Placebo
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
8
States / cities
Denver, Colorado • Bethesda, Maryland • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2018 · Synced Sep 6, 2026, 2:56 PM EDT
Completed Phase 3 Interventional Results available

Cessation Versus Continuation of Long-term Mepolizumab in Severe Eosinophilic Asthma Patients

NCT02555371
View directory record Official record
Conditions
Asthma
Interventions
Mepolizumab 100mg, Placebo
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
306 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
13
States / cities
Long Beach, California • Riverside, California • Denver, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2020 · Synced Sep 6, 2026, 2:56 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Mepolizumab Adjunctive Therapy in Participants With Severe Eosinophilic Asthma on Markers of Asthma Control

NCT02281318
View directory record Official record
Conditions
Asthma
Interventions
Mepolizumab, Placebo, SOC
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
556 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
24
States / cities
Birmingham, Alabama • Fresno, California • Long Beach, California + 20 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2018 · Synced Sep 6, 2026, 2:56 PM EDT